For Investors

Investor Relations

Latest Press Releases

All Press Releases

Date	Title
January 2, 2020	Novan Reports Top-Line Efficacy Results from Phase 3 Trials of SB206 for Molluscum Contagiosum
December 18, 2019	Novan Announces Planned Chief Executive Officer Transition
October 18, 2019	Novan Further Expands its Proprietary Nitric Oxide Platform
October 8, 2019	Novan’s Phase 2 SB206 Molluscum Study Published in Journal of the American Academy of Dermatology

Recent SEC Filings

All SEC Filings

Filing date	Form	Filing Group	View
January 03, 2020	8-K	Current Reports	0001467154-20-000002.rtf 0001467154-20-000002.xls 0001467154-20-000002.pdf
December 18, 2019	8-K	Current Reports	0001467154-19-000106.rtf 0001467154-19-000106.xls 0001467154-19-000106.pdf
November 12, 2019	10-Q	Quarterly Filings	0001467154-19-000103.rtf 0001467154-19-000103.xls 0001467154-19-000103.pdf
September 16, 2019	424B3	Registration Statements	0001467154-19-000098.rtf 0001467154-19-000098.xls 0001467154-19-000098.pdf

Upcoming Events

Stock Information

Exchange
Volume
Today's Open
Previous Close

Data as of Jan 24, 2020 1:26 AM EST

Copyright West LLC. Minimum 15 minutes delayed.

Corporate Governance

Click here to view our Corporate Governance information.

IR & Media Contact

Cole Ikkala
Director, Investor Relations, Communications & Business Development
cikkala@novan.com

Information Request

Click here to request information.

Presentation

Annual Report

Analyst Coverage

Firm	Analyst
JMP Securities	Donald Ellis Pharm.D.
Piper Jaffray & Co.	David Amsellem
H.C. Wainwright & Co.	Oren Livnat

Transfer Agent

American Stock Transfer & Trust Company, LLC
www.amstock.com

E-mail Alerts

Sign up here to get latest notifications whenever Novan inc. posts new information to the site.